2.45
-0.11(-4.30%)
Currency In USD
Address
1180 Seminole Trail
Charlottesville, VA 22901
United States of America
Phone
434 422 9800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
July 27, 2018
| Name | Title | Pay | Year Born |
| Cary John Claiborne | Chief Executive Officer, President & Director | 561,331 | 1961 |
| Tony Goodman | COO & Director | 342,828 | 1964 |
| Andrew Taubman | Vice President of Corporate Development | 0 | N/A |
| Brigitte Robertson | Acting Chief Medical Officer | 0 | 1964 |
| Abel Svitavsky | Controller | 0 | N/A |
| John R. Martin | Chief Legal Officer | 0 | N/A |
| Vinay Shah | Chief Financial Officer & Treasurer | 0 | 1963 |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.